Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
16 January 2014

Bionomics Presents Data on Novel Antibody Approach to Targeting Cancer Stem Cells at Leading US Conference

Bionomics Limited (ASX: BNO) (ADR: BMICY) Vice-President of Research and Development Biologics Dr Christopher Reyes will today present data on the company's multispecific antibody BNC102 that simultaneously targets two cancer stem cell receptors. The presentation is at the 2014 PEPTALK "New Approaches for Creating Efficacious Bispecifics" meeting in Palm Springs CA, USA.

Highlights of today's presentation include:

- Overview of Bionomics' validated Cancer Stem Cell (CSC) Rx Discovery platform used to develop the multispecific antibody and other promising anti-CSC therapeutic candidates in Bionomics' oncology pipeline
- Introduction to multispecific antibody technology
- Biological rationale for targeting LGR5 and LGR4 with a multispecific antibody
- Demonstration of significant *in vivo* anti-tumour activity and reduction of the population of cancer stem cells in multiple patient-derived tumour (PDX) models.

Dr Reyes will also chair the afternoon session entitled "Bispecific Antibody Therapeutics – Enhancing Properties" on Friday 17 January 2014.

The PEPTALK meeting comprises of over 1,200 participants from 20 countries drawing leaders of biotherapeutics from industry and academia pioneering the evolution of biologics.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited
Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co and Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.